AcuraStem’s best-in-class disease modeling platform, iNeuroRx, enables the discovery of innovative, effective, and broadly acting treatments.

In September 2023, AcuraStem entered into a license agreement with Takeda to develop and commercialize AcuraStem’s PIKFYVE targeted therapeutics including AS-202, an innovative antisense oligonucleotide for the treatment of ALS.